Cambrian Bio

📍 New York, United States🗓 Founded 2019👥 29 employees💰 Last funded May 2024
Biotechnology Research🌐 cambrianbio.com
Website LinkedIn
Cambrian Bio is a clinical-stage drug development company building the medicines that will modernize healthcare in the 21st century. Our focus lies in creating innovative therapeutics designed to treat and ultimately prevent some of todays most debilitating chronic diseases, including platforms targeting the critical metabolic pathways that decline with age such as AMPK activation, mitochondrial function, and mTORC1 inhibition, to extend the period of life spent in good health.
6
Total investors
4
Early stage
2
Mid stage
0
Late stage
2019
Founded

Investors

6 investors
All
Early stage
Mid stage
Late stage
Investor geography3 countries
United States
4
Hong Kong
1
United Kingdom
1
Investor activity2019–2024 · investors recorded per year
20192202012021120242
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Cambrian Bio?
Cambrian Bio has 6 investors on record on gritt.io, including 4 early-stage backers, 2 mid-stage.
When did Cambrian Bio last raise funding?
The most recent investment in Cambrian Bio recorded on gritt.io was in May 2024.
When was Cambrian Bio founded?
Cambrian Bio was founded in 2019.
What industry is Cambrian Bio in?
Cambrian Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Cambrian Bio based?
Cambrian Bio is headquartered in New York, United States.